Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLCMarcelo V. Negrão, Sandip Pravin Patel, Haniel A. Araújo et al.|Cancer Discovery|2023Cited by 181
Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective studyMaliazurina B. Saad, Jia Wu, Lingzhi Hong et al.|The Lancet Digital Health|2023Cited by 108
Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancerBiagio Ricciuti, Jia Luo, Victor R. Vaz et al.|Annals of Oncology|2022Cited by 100